PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Novartis and Ratio Enter Radiotherapeutics Partnership Worth $745m

Novartis and Ratio Therapeutics have entered into a worldwide licence and collaboration agreement worth $745m to advance a somatostatin receptor 2 (SSTR2)-targeting ...
Continue Reading →
News

Roche completed the repurchase of Roche shares from Novartis

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November 2021, Roche and Nov...
Continue Reading →
News

NICE recommends first sickle cell disease treatment in two decades

The National Institute for Health and Care Excellence (NICE) has recommended that a new therapy for sickle cell disease is made available on the NHS for the first ti...
Continue Reading →
News

NICE recommends Novartis’ secukinumab for children with moderate to severe psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Cosentyx® (secukinumab) as an option for treating moderate to severe plaque ps...
Continue Reading →
News

Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial

The Phase III Belinda study investigating Kymriah (tisagenlecleucel) for treatment of non-Hodgkin lymphoma did not meet its primary endpoint of event-free survival c...
Continue Reading →
News

Trump coaxes big promises from big pharma

Several drug industry giants are now pledging to freeze price increases in the US, but some suggest the movement is a publicity stunt or worse Amid significant press...
Continue Reading →
News

Novartis and Amgen Highlight Findings from a Large Global Patient Survey on Migranes

Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on avera...
Continue Reading →
News

Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?

  Novartis’ breast cancer drug Kisqali so far hasn’t lived up to expectations, and the drugmaker’s hoping some strong new data in metastatic patients will ...
Continue Reading →
News

Novartis general counsel to step down after payments to Trump's lawyer

Novartis AG's top lawyer became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Trump's attorney...
Continue Reading →
News

FDA approval for Novartis' melanoma combo

The FDA has approved Novartis' Tafinlar(dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of BRAF V600E or V600K mutation-positiv...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026